Whalesbook
Medanta, operated by Global Health, delivered a strong performance in the fourth quarter of fiscal year 2026. Revenue increased by 25% year-over-year to Rs 1,159 crore, and profit after tax surged by 42% to Rs 144 crore, resulting in a profit margin of 12.4%. Operating EBITDA reached Rs 244 crore, with a margin of 21.0%. These results reflect healthy operational trends across its established hospitals.
Expansion Plans and Noida Facility
The company plans to add approximately 500 beds in its existing hospitals in the near term. Looking further ahead, Medanta has an ambitious plan to add around 2,700 beds across five new greenfield projects over the next three to four years. The newly commissioned Noida hospital is a key focus, with its EBITDA losses narrowing to Rs 23.6 crore in Q4FY26 from Rs 32.0 crore in the previous quarter, showing steady progress. Management anticipates the Noida facility will reach breakeven in the second half of FY27, a significant milestone that could greatly boost future earnings. Medanta maintains a strong balance sheet, ending FY26 with Rs 590 crore in net cash and Rs 714 crore in operating cash flow.
Competitive Landscape and Valuation
Medanta aims for 12-15% compound annual growth in the Indian hospital sector, driven by rising healthcare spending and awareness. However, it operates in a competitive market. Major players like Apollo Hospitals (Market Cap ~Rs 75,000 crore), Max Healthcare (Market Cap ~Rs 38,000 crore), and Fortis Healthcare (Market Cap ~Rs 27,000 crore) are also expanding. Medanta's valuation of approximately 23 times its estimated future earnings (EV/EBITDA) for FY28 appears reasonable compared to these competitors. The Indian healthcare sector is poised for growth due to increasing disposable incomes and medical tourism, but faces challenges from evolving regulations and competition for skilled professionals.
Key Risks to Monitor
Medanta's extensive expansion pipeline, involving about 2,700 new beds, requires substantial investment and depends heavily on successful execution. Delays in project completion or slower-than-expected progress at new sites, like the Noida hospital, could significantly affect financial results and strain its finances, despite its current net cash position. The Noida facility is currently operating at about 30% occupancy; failing to reach breakeven in H2FY27 as guided would be a major setback. The industry also faces potential regulatory changes, such as pricing controls, and increasing competition in urban markets could lead to pricing pressures and higher costs for talent. Compared to more diversified healthcare groups, Medanta's growth is concentrated on hospital operations, making it more susceptible to sector-specific challenges. Management's ability to deliver large projects on time and within budget will be a key factor in future success.
Outlook for FY27
For FY27, Medanta expects growth to be driven by the Noida hospital's ramp-up and breakeven, additional beds in existing facilities, expanding procedural capacity, and scaling its international business. Management projects capital expenditure between Rs 800-900 crore for FY27, indicating continued investment. The company is also open to inorganic acquisition opportunities that fit its strategy. Analyst reports generally forecast continued earnings growth, provided expansion plans are executed successfully and newer facilities normalize operations.